[HDV] iShares Trust

Overview

Type of security: Fund

Tags: Country, Dividend, Equity, ETF, High Dividend Yield, Index Based, Not Inversed, U.S., Unleveraged

The data is delayed by 15 minutes.

 

Price: 82.74 Change: -0.03 (-0.04%)
Ext. hours: Change: 0 (0%)

chart HDV

Refresh chart

Strongest Trends Summary For HDV

HDV is in the long-term up 124% in 11 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: The investment seeks to track the investment results of an index composed of relatively high dividend paying U.S. equities. The fund generally invests at least 90% of its assets in the securities of the underlying index or in depositary receipts representing securities of the underlying index. It seeks to track the investment results of the Morningstar® Dividend Yield Focus IndexSM (the "underlying index"), which offers exposure to high quality U.S.-domiciled companies that have had strong financial health and an ability to sustain above average dividend payouts. The fund is non-diversified.

Technical Data
High 52 week92.44 Low 52 week81.47 Last close88.84 Last change-0.77%
RSI49.82 Average true range1.05 Beta0.7 Volume310.97 K
Simple moving average 20 days-1.03% Simple moving average 50 days-1.19% Simple moving average 200 days2.71%
Performance Data
Performance Week-1.88% Performance Month1.47% Performance Quart-0.11% Performance Half5.96%
Performance Year5.62% Performance Year-to-date0.44% Volatility daily0.82% Volatility weekly1.84%
Volatility monthly3.78% Volatility yearly13.08% Relative Volume229.53% Average Volume653.17 K
New High New Low
Funds Characteristics
30-day SEC yield Average market capitalization Average weighted market capitalization Forward P/E
Gross expense ratio Index dividend yield Median market cap Number of holdings75
Price to Book Value 3.75 Price to Earnings18.94 Total expense ratio0.12% Total net assets3.47 B
Weighted market capitalization

Info

Characteristics:
NAME VALUE
Total Expense Ratio0,12
Number Of Holdings75
Total Net Assets3 468 877 901,00
P/E Ratio18,94
P/Bv Ratio3,75
Top Holdings:
NAME VALUE
Att Inc9,94
Chevron Corp7,49
Johnson Johnson7,4
Pfizer Inc6,41
Procter Gamble6,3
Philip Morris International Inc5,9
Merck Co Inc4,86
Intel Corp4,41
Coca-cola4,05
Altria Group Inc3,77
Sector Breakdown:
NAME VALUE
Consumer Goods24,35
Health Care20,5
Utilities13,65
Communication Services11,23
Energy7,49
Technology7,09
Oil Gas5,21
Others3,74
Consumer Cyclical3,03
Basic Materials2,09
Consumer Defensive1,38

News

2018-12-24 14:10:07 | A Dividend ETF Investing Guide

2018-11-20 13:10:45 | Merck’s Stock Price Has Increased ~34% in 2018

2018-11-15 16:54:47 | Top ETFs: As Dividends Compare More Favorably, IShares ETF Emerges As A Leader

2018-10-31 09:32:10 | How Wall Street Analysts View Merck

2018-10-30 10:30:04 | 37% of Analysts Rate 3M as a ‘Buy’ after Its Q3 2018 Earnings

2018-10-25 07:30:16 | How Is Johnson & Johnson’s Vision Care Business Positioned?

2018-10-19 10:31:44 | What’s Pfizer’s Current Valuation?

2018-10-19 10:05:02 | A Guide to Dividend ETF Investing

2018-10-15 14:20:02 | What’s Expected for Merck’s Q3 2018 Earnings

2018-10-01 07:34:42 | Pfizer’s Dividend Growth Trend and Analysts’ Recommendations

2018-09-07 15:09:46 | 7 Inexpensive High Dividend ETFs to Buy

2018-07-13 16:17:19 | Dividend ETFs: Capitalizing on a Trump Bump?

2018-05-10 09:00:52 | Merck’s Post-1Q18 Valuation

2018-04-26 09:00:25 | What’s Johnson & Johnson’s Valuation after 1Q18 Earnings?

2018-04-16 08:06:32 | Analysts’ Recommendations for Johnson & Johnson on April 16

2018-04-04 10:15:10 | 3 Top Low-Cost Dividend Funds to Buy

2018-03-31 06:16:00 | Should Dividends Still Matter To Stockholders?

2018-03-01 12:22:05 | Factors that Could Drive Dominion Energy’s Dividend Growth

2018-02-06 12:38:18 | A Venerable Dividend ETF for Conservative Investors

2018-01-10 15:30:02 | Why The Kraft Heinz Company’s Outlook Still Seems Promising

2018-01-10 13:45:00 | 5 ETFs to Bet on 2018 Dogs of the Dow

2018-01-03 12:54:00 | A Dependable Dividend ETF For 2018

2017-10-25 07:41:12 | What Do Analysts Think about Merck?

2017-09-15 16:07:01 | Nervous Investor? Consider These 3 Dividend ETFs

2017-09-11 12:32:17 | Decoding Helmerich & Payne’s Dividend Yield

2017-08-31 10:36:32 | A Post-2Q17 Update on Pfizer’s Oncology Drugs: Sutent, Xalkori, and Inlyta

2017-08-25 10:52:42 | Dividend ETFs Can Shine Again After Trailing Market

2017-08-23 12:42:46 | Dividend Yield of Procter & Gamble

2017-08-23 10:55:02 | 5 Cheap Dividend ETFs for an Uncertain Market

2017-08-16 09:32:53 | Consolidated Edison’s Dividend Trajectory

2017-08-15 10:36:03 | Pfizer’s Corporate and Pipeline Developments in 2Q17

2017-08-01 10:13:05 | Revisiting Some High Dividend ETFs

2017-07-27 07:36:11 | Pfizer Sees a Significant Opportunity in This for Revenue Growth

2017-07-23 20:15:00 | 3 Dividend ETFs to Keep You Invested After Retirement

2017-07-18 09:07:59 | Can Delta Continue to Be the Best Airline Dividend Payer?

2017-07-12 14:44:06 | The Top Dividend-Growing Financial Sector Stocks

2017-07-07 11:49:09 | IBM’s Dividend Growth Curve

2017-07-05 07:35:50 | Merck’s Immunology and Cardiovascular Franchise in 1Q17

2017-06-28 07:36:35 | Pfizer’s Segment Performance in 1Q17

2017-06-22 08:00:22 | Which Of These 2 Foreign Stock Plays Owns This Top Beer Maker?

2017-06-22 07:38:18 | Comparing Growth and Value Stock Sectors

2017-06-20 09:00:44 | 2 Big Dividend Plays Near Buy Point; Which One Owns Microsoft?

2017-06-08 07:36:38 | Understanding Pfizer’s 1Q17 Performance by Geography

2017-06-01 10:37:56 | Eli Lilly’s Business Segments’ Performance in 1Q17

2017-05-29 10:37:56 | TOT, SU, E, and PBR: Comparing Their Dividend Yields

2017-05-19 10:36:03 | Is BP’s Cash Flow Slated for Growth?

2017-05-19 06:00:00 | Not All High Dividend ETFs Are Taking a Breather

2017-05-10 17:05:43 | Who Has Higher Dividend Yields: RDS.A, XOM, CVX, or BP?

2017-05-02 09:06:39 | Performance of Eli Lilly & Co.’s Elanco in 1Q17

2017-04-21 07:36:48 | Eli Lilly’s 1Q17 Estimates for Humalog, Other Endocrine Products